Glythera gains exclusive access to novel CDK11 inhibitor program to develop ADCs

Glythera has paid an undisclosed sum for exclusive access to Cancer Research UK’s novel CDK11 inhibitor program to develop antibody drug conjugates (ADCs) using the biotech company’s proprietary PermaLink conjugation platform.

This agreement follows a successful between the two parties during which the viability of selected low molecular weight CDK11 molecules was demonstrated in relevant ADC models.

The UK charity will also receive milestone payments on program success for each resulting ADC, and royalties on any worldwide product sales.